Organon & Co. (OGN) Stock Price, News & Analysis

Company Overview

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Key Stats

• Today's Range: $9.88 to $10.24
• 50-Day Range: $8.05 to $13.21
• 52-Week Range: $8.01 to $23.10
• Volume: 3.34 million shs
• Average Volume: 3.42 million shs
• Market Capitalization: $2.61 billion
• P/E Ratio: 3.01
• Dividend Yield: 0.80%
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Organon & Co. Stock Analysis - MarketRank™

Organon & Co. scored higher than 96% of companies evaluated by MarketBeat, and ranked 38th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Organon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Organon & Co. has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 1.63%

Earnings Growth

Earnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organon & Co. is 3.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.26.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organon & Co. is 3.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.63.

Price to Earnings Growth Ratio

Organon & Co. has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.75% of the float of Organon & Co. has been sold short.

Short Interest Ratio / Days to Cover

Organon & Co. has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Organon & Co. has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Organon & Co. has a dividend yield of 0.87%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Organon & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Organon & Co. is 2.78%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.14% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.37

Percentage of Shares Shorted

6.75% of the float of Organon & Co. has been sold short.

Short Interest Ratio / Days to Cover

Organon & Co. has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Organon & Co. has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.04

News Sentiment

Organon & Co. has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for Organon & Co. this week, compared to 9 articles on an average week.

Search Interest

Only 19 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -85% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Organon & Co. insiders have bought more of their company's stock than they have sold. Specifically, they have bought $902,430.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.96% of the stock of Organon & Co. is held by insiders.

Percentage Held by Institutions

77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OGN Stock Analysis - Frequently Asked Questions

How have OGN shares performed this year?

Organon & Co.'s stock was trading at $14.92 at the start of the year. Since then, OGN shares have decreased by 32.8% and is now trading at $10.0250.
View the best growth stocks for 2025 here.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) posted its earnings results on Thursday, May, 1st. The company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.13. The firm's quarterly revenue was down 6.7% compared to the same quarter last year.
Read the conference call transcript.

Who are Organon & Co.'s major shareholders?

Top institutional investors of Organon & Co. include Vanguard Group Inc. (11.43%), Massachusetts Financial Services Co. MA (4.12%), LSV Asset Management (3.07%) and Sound Shore Management Inc. CT (1.91%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Kirke Weaver and Daniel Karp.
View institutional ownership trends.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organon & Co. own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM).

Company Calendar

• Last Earnings: 5/01/2025
• Record date for 6/12 Dividend: 5/12/2025
• Ex-Dividend for 6/12 Dividend: 5/12/2025
• Dividend Payable: 6/12/2025
• Today: 6/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGN
• CIK: 1821825
• Web: www.organon.com
• Phone: 551-430-6900
• Fax: N/A
• Employees: 10,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.00
• High Stock Price Target: $24.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +79.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.88
• Trailing P/E Ratio: 3.01
• Forward P/E Ratio: 2.72
• P/E Growth: 0.9
• Net Income: $864 million
• Net Margins: 13.49%
• Pretax Margin: 12.60%
• Return on Equity: 431.62%
• Return on Assets: 8.03%

Debt

• Debt-to-Equity Ratio: 17.73
• Current Ratio: 1.70
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $6.29 billion
• Price / Sales: 0.41
• Cash Flow: $3.21 per share
• Price / Cash Flow: 3.12
• Book Value: ($0.27) per share
• Price / Book: -37.13

Miscellaneous

• Outstanding Shares: 259,956,000
• Free Float: 253,933,000
• Market Cap: $2.61 billion
• Optionable: Not Optionable
• Beta: 0.58